AxoGen, Inc. $AXGN Shares Purchased by Driehaus Capital Management LLC

Driehaus Capital Management LLC increased its position in shares of AxoGen, Inc. (NASDAQ:AXGN) by 22.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,172,029 shares of the medical equipment provider’s stock after purchasing an additional 217,590 shares during the period. Driehaus Capital Management LLC’s holdings in AxoGen were worth $21,683,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of AXGN. State of Wyoming acquired a new position in shares of AxoGen during the fourth quarter worth $31,000. Fifth Third Bancorp acquired a new position in shares of AxoGen during the first quarter worth $92,000. GAMMA Investing LLC grew its stake in shares of AxoGen by 3,884.6% during the first quarter. GAMMA Investing LLC now owns 5,698 shares of the medical equipment provider’s stock worth $105,000 after purchasing an additional 5,555 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of AxoGen during the first quarter worth $146,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of AxoGen during the first quarter worth $150,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Price Performance

Shares of AXGN opened at $16.14 on Friday. AxoGen, Inc. has a 1-year low of $9.22 and a 1-year high of $21.00. The stock has a market cap of $742.60 million, a PE ratio of -161.38 and a beta of 1.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.14 and a quick ratio of 2.67. The firm has a fifty day moving average price of $13.02 and a 200 day moving average price of $14.43.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group reduced their price target on shares of AxoGen from $26.00 to $24.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. Wall Street Zen raised shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $26.00.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.